Zobrazeno 1 - 9 of 9 pro vyhledávání: '"Janet Ogden"'
1
Translational Medicine Guide transforms drug development processes: the recent Merck experience
Autor: Ewen Sedman, Joern-Peter Halle, Dietmar Gross, Luciano Rossetti, Mark R. Trusheim, Bruno Osterwalder, Janet Ogden, Hugues Dolgos
Publikováno v: Drug Discovery Today. 21:517-526
Merck is implementing a question-based Translational Medicine Guide (TxM Guide) beginning as early as lead optimization into its stage-gate drug development process. Initial experiences with the TxM Guide, which is embedded into an integrated develop
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbc362864d57c45eb91a6a483c11df10
https://doi.org/10.1016/j.drudis.2016.01.003
Zobrazit plný text záznamu
3
Abstract 2603: Combination activity of the MEK inhibitor Pimasertib and the hypoxia-activated prodrug TH-302 in pancreatic and biliary tract tumor xenograft models
Autor: Sakeena Syed, Lindsey Crowley, Janet Ogden, Jamie Shaw, Jianguo Ma, Brian Elenbaas, Samantha Goodstal
Publikováno v: Cancer Research. 75:2603-2603
The efficacy and tolerability of the MEK inhibitor Pimasertib and the hypoxia-activated prodrug TH-302 combination were explored in pancreatic and biliary tract preclinical tumor xenograft models. These studies were based on the hypotheses that combi
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::61cd16af28d6c8cddcfd532094e0809a
https://doi.org/10.1158/1538-7445.am2015-2603
Zobrazit plný text záznamu
4
Abstract A48: Anti-tumor activity of the MEK inhibitor pimasertib in combination with the PI3K/mTOR inhibitor SAR245409 in low-grade serous ovarian cancer
Autor: Karl Hsu, Loic Vincent, Sukhvinder S. Sidhu, Janet Ogden, Lars Damstrup, Ekaterine Asatiani, Samantha Goodstal, Coumaran Egile, Frank Campana, Joanne Lager
Publikováno v: Clinical Cancer Research. 19:A48-A48
Low-grade serous ovarian carcinoma is a distinct neoplasm from high-grade serous ovarian carcinoma and is chemo-resistant, both in the first line setting as well as in subsequent lines of therapy. Serous ovarian tumors of low malignant potential and
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a0685bc65bbb2ea939525545baabdcf6
https://doi.org/10.1158/1078-0432.ovca13-a48
Zobrazit plný text záznamu
5
Combination of a MEK inhibitor, pimasertib (MSC1936369B), and a PI3K/mTOR inhibitor, SAR245409, in patients with advanced solid tumors: Results of a phase Ib dose-escalation trial
Autor: Janet Ogden, Karl Hsu, José Baselga, Rebecca S. Heist, Loic Vincent, Howard A. Burris, Naiyer A. Rizvi, Leena Gandhi, Oliver von Richter, Giuseppe Locatelli, E. Asatiani, Jeffrey R. Infante, Scott B Yerganian, Johanna C. Bendell, Geoffrey I. Shapiro
Publikováno v: Journal of Clinical Oncology. 31:2530-2530
2530 Background: PI3K/mTOR and MAPK signaling pathways are often deregulated in tumors. Simultaneous inhibition of these pathways with the MEK1/2 inhibitor, pimasertib, plus the dual PI3K/mTOR inhibitor, SAR245409, (ClinicalTrials.gov NCT01390818) wa
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d484914fbaca0e8c0826efea3c104943
https://doi.org/10.1200/jco.2013.31.15_suppl.2530
Zobrazit plný text záznamu
8
Abstract LB-456: Evaluation of brain pharmacokinetics as a potential differentiation factor for the MEK inhibitors, MSC2015103 and pimasertib
Autor: Riham Carden, Samantha Goodstal, Anderson Clark, Daniel Qiu, Hui Tian, Jamie V. Shaw, Jianguo Ma, Janet Ogden, Hong Zhang
Publikováno v: Cancer Research. 72:LB-456
MSC2015103 is an orally bio-available, selective, and highly potent small molecule inhibitor of MEK1/2. As a follower to the front-runner MEK inhibitor, pimasertib (MSC1936369/AS703026), a prime objective for the program is to differentiate the two c
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::cb032e298cba48b0ca7783553826fac1
https://doi.org/10.1158/1538-7445.am2012-lb-456
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje